Rinvoq vs. Simponi

• Are Rinvoq and Simponi the Same Thing?
• What Are Possible Side Effects of Rinvoq?
• What Are Possible Side Effects of Simponi?
• What Is Rinvoq?
• What Is Simponi?
• What Drugs Interact with Rinvoq?
• What Drugs Interact with Simponi?
• How Should Rinvoq Be Taken?
• How Should Simponi Be Taken?

Rinvoq (upadacitinib) and Simponi (golimumab injection) are used to treat rheumatoid arthritis.

Simponi is also used to treat psoriatic arthritis and ankylosing spondylitis. Simponi is sometimes used with another medication called methotrexate (Rheumatrex, Trexall).

Rinvoq and Simponi belong to different drug classes. Rinvoq is a Janus kinase (JAK) inhibitor and Simponi is a tumor necrosis factor (TNF) blocker.

Side effects of Rinvoq that are different from Simponi include upper respiratory tract infections, nausea, cough, and fever.

Side effects of Simponi that are different from Rinvoq include dizziness, cold symptoms (stuffy nose, sneezing, sore throat), and injection site reactions (redness, itching, pain, or swelling).

Both Rinvoq and Simponi may interact with live vaccines.

Rinvoq may also interact with strong CYP3A4 inhibitors (e.g., ketoconazole) and strong CYP3A4 inducers (e.g., rifampin).

Simponi may also interact with abatacept, anakinra, rituximab, blood thinners, cyclosporine, digoxin, theophylline, seizure medications, and heart rhythm medications.

Common side effects of Rinvoq include:

• upper respiratory tract infections,
• nausea,
• cough, and
• fever

Side effects of Simponi nclude<:/p>

• dizziness,
• cold symptoms (stuffy nose, sneezing, sore throat), or
• injection site reactions (redness, itching, pain, or swelling).

Tell your doctor if you have serious side effects of Simponi including:

• easy bruising or bleeding,
• numbness or tingling of the hands or feet,
• unsteadiness,
• unexplained muscle weakness,
• vision changes,
• muscle or joint pain,
• butterfly-shaped rash on the nose and cheeks,
• symptoms of heart failure (including swelling ankles or feet, trouble breathing, unusual tiredness),
• signs of infection (such as fever/chills/cough/persistent sore throat, unusual sweating), or
• symptoms of liver damage (including dark urine, persistent nausea/vomiting/loss of appetite, stomach/abdominal pain, or yellow eyes or skin).

Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Simponi (golimumab injection) is a human IgG1k monoclonal antibody used to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Simponi is sometimes used with another medication called methotrexate (Rheumatrex, Trexall). Simponi works by blocking a protein (tumor necrosis factor or TNF) found in the body's immune system that causes joint swelling and damage.

Rinvoq may interact with strong CYP3A4 inhibitors (e.g., ketoconazole), strong CYP3A4 inducers (e.g., rifampin), and live vaccines. Tell your doctor all medications and supplements you use. Rinvoq is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Rinvoq and for 4 weeks following completion of therapy. It is unknown if Rinvoq passes into breast milk. Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with Rinvoq, and for 6 days after the last dose.

Simponi may interact with abatacept, anakinra, rituximab, blood thinners, cyclosporine, digoxin, theophylline, seizure medications, or heart rhythm medications. Tell your doctor all medications you use. During pregnancy, Simponi should be used only when prescribed. It is unknown if this drug passes into breast milk. Because of the potential risk to the infant, consult your doctor before breastfeeding.

The recommended dose of Rinvoq is 15 mg once daily. Rinvoq may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.

The Simponi dose regimen is 50 mg administered by subcutaneous (SC) injection once a month.